帕金森病患者采取美多芭联合司来吉兰治疗的效果及安全性观察

Efficacy and safety of madopar combined with selegiline treating on patients with parkinson's disease

目的探讨美多芭联合司来吉兰治疗帕金森病患者的临床效果和安全性。方法选择本院收治的帕金森患者98例,以简单随机法分为对照组与联合组,各49例。对照组采取美多芭治疗,联合组采取美多芭联合司来吉兰治疗,对两组患者临床治疗效果和安全性进行观察比较。结果治疗后联合组Webster、UPDRS评分均低于对照组(P<0.05);联合组治疗总有效率高于对照组(P<0.05);两组不良反应情况对比,差异不显著(P>0.05)。结论美多芭联合司来吉兰治疗可改善帕金森病患者各项临床症状,提高治疗有效率,且不良反应发生率低,值得临床推广。

Objective To investigate the clinical efficacy and safety of madopar combined with selegiline treating on patients with parkinson's disease.Methods Ninety-eight patients with parkinson's disease were randomly divided into control group and combination group,with49cases in each group.The control group was treated with madopar.The combination group was treated with madopar combined with selegiline.The clinical efficacy and safety of the two groups were compared.Results After treatment the Webster and UPDRS scores of the combination group were lower than those of the control group(P<0.05).The total effective rate of the combined group was higher than that of the control group(P<0.05).There was no significant difference in the adverse reactions between the two groups(P>0.05).Conclusion Madopar combined with selegiline can improve the clinical symptoms of patients with parkinson's disease,improve the efficiency of treatment,with lower incidence of adverse reactions,which is worthy of clinical promotion.